New Myriad Genetics Published Study Demonstrating PPV For 22122.2 Microdeletion Screening Using Prequel Prenatal Screen
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics has published a new study showcasing the positive predictive value (PPV) of its Prequel Prenatal Screen for 22q11.2 microdeletion, a genetic disorder. This development could enhance the company's reputation in genetic testing and potentially increase demand for the Prequel Prenatal Screen.
April 16, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The publication of the study may positively impact Myriad Genetics by reinforcing its position in the prenatal genetic testing market and potentially increasing demand for its Prequel Prenatal Screen.
The publication of a successful study directly impacts Myriad Genetics by potentially increasing the credibility and demand for its Prequel Prenatal Screen. This could lead to increased sales and a stronger market position in the genetic testing industry, particularly for prenatal screenings.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90